Nifedipine sustained-release tablets (Ⅱ)

Nifedipine is a dihydropyridine calcium antagonist that selectively inhibits the transmembrane transport of calcium ions into myocardial cells and smooth muscle cells, and inhibits the release of calcium ions from intracellular pools without changing the plasma calcium ion concentration. Pharmacological action This product can simultaneously relax the coronary arteries in the normal blood supply area and the ischemic area, antagonize spontaneous or ergonovine-induced coronary artery spasm, increase the delivery of myocardial oxygen in patients with coronary artery spasm, and relieve and prevent coronary artery spasm. It can also inhibit myocardial contraction, reduce myocardial metabolism, and reduce myocardial oxygen consumption. On the other hand, it can relax peripheral resistance vessels, reduce peripheral resistance, reduce systolic and diastolic blood pressure, and reduce cardiac afterload. This product can delay the sinus node function and atrioventricular conduction of isolated hearts; electrophysiological studies of whole animals and humans have not found that this product has the effect of delaying atrioventricular conduction, prolonging the recovery time of the sinus node, and slowing down the sinus node rate. Toxicological action Carcinogenicity, mutagenicity and reproductive toxicity No carcinogenicity. No mutagenicity. Large doses can reduce the fertility of female mice, cause teratogenesis, and induce abortion (increased drug absorption rate in fetal mice, increased fetal mortality, and decreased survival rate of newborn mice). Pregnant monkeys taking 2/3-2 times the maximum human dose can cause small placenta and chorionic dysplasia; giving rats 3 times the maximum human dose can cause prolonged pregnancy.

The main ingredient of this product is nifedipine, and its chemical name is: 2,6-dimethyl-4 (2-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylic acid dimethyl ester. Its structural formula is: Molecular formula: C17H18N2O6 Molecular weight: 346.34

Thin-coated tablets, yellow in color after removing the film coating.

Used to treat hypertension and angina pectoris.

Oral administration: 1 tablet at a time, 1 to 2 times a day, or as directed by a doctor.

1. The reaction is short-lived and the most common symptoms are swelling of the ankles, feet and calves, which can be relieved by taking diuretics. 2. Occasionally, chest pain, headache, flushing, dizziness, palpitations, and decreased blood pressure may occur. 3. Occasionally, abdominal pain, nausea, loss of appetite, constipation, etc. may occur. 4. Gum hypertrophy may occur.

1. Patients allergic to nifedipine are contraindicated. 2. Patients with cardiogenic shock.

Precautions for children: Children are prohibited from using this product. Precautions for pregnancy and lactation: Pregnant women are prohibited from using this product. Clinical studies on lactating mothers are not sufficient. It is best not to breastfeed when taking this product. Precautions for the elderly: After taking this product, its half-life is prolonged, and Cmax and AUC are increased. Be careful to start taking it from the lowest dose to reduce the incidence of adverse reactions.

1. Combined with nitrates, it can control angina attacks and has good tolerance. 2. Combined with β-receptor blockers, most patients have good tolerance and efficacy for this product, but some patients may induce and aggravate hypotension, heart failure and angina. 3. Combined with digitalis, it may increase the blood digoxin concentration, suggesting that the blood concentration of digoxin should be monitored when using it for the first time, adjusting the dose or stopping this product. 4. Combined with drugs with high protein binding rate, such as dicoumarols, phenytoin sodium, quinidine, quinine, warfarin, etc., the free concentration of these drugs often changes. 5. Combined with cimetidine, the peak plasma concentration of this product increases, pay attention to adjust the dose. 6. When grapefruit juice is taken with this product, the Cmax and AUC of this product increase.

Keep in a light-proof and airtight container.

20 mg

36 months

Zhejiang Weikang Pharmaceutical Co., Ltd.

• Founded in:

  2002-12-27

• Address:

  No. 15, Xinggong North Road, Jiangshan Economic Development Zone, Zhejiang Province

• Tax NO.:

  91330881753003855U

• Registered Funds:

  8.15 million yuan

• Website:

  Log in to view

• Email:

  Log in to view